Alpha Cognition Inc. (ACOG): Targets Long-Term Care Market with Innovative Solutions

Securing Medicare reimbursement for ZUNVEYL expands patient access and underscores the therapy's clinical value. This development is expected to drive adoption within the long-term care sector.

Alpha Cognition Inc. (ACOG) is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases, notably Alzheimer’s disease and cognitive impairment associated with mild traumatic brain injury (mTBI). Their lead product, ZUNVEYL® (benzgalantamine), is an FDA-approved oral therapy for mild-to-moderate Alzheimer’s, designed to …